Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 401 - 408 of 11439 results
New Legislative Session, New Attempts at Banning Non-Competes in New York (City)
March 13, 2024| Blog| Viewpoint
Why The SEC Climate Rule Might Not Standardize Emissions Reporting
March 13, 2024| News
FDA Needs a New Approach to AI/ML-Enabled Medical Devices
March 12, 2024| Blog| Viewpoint
Compliance with the New York LLC Transparency Act Necessary for Many Mintz Clients
March 12, 2024| Alert| Viewpoint
Side Letter: CalPERS' Co-invest Conviction
March 12, 2024| News
Former Lab Owners, Compliance Officer Face Prison Time Over False Claims
March 12, 2024| News
New Mexico’s Health Care Consolidation Oversight Act: An Overview
March 11, 2024| Blog| Viewpoint
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.